PeptideLabs Logo
PeptideLabs
All profiles

Thymosin Alpha-1

Peptide · Immune research

Studied for immune modulation and approved for specific uses in some countries, but not generally by FDA or EMA.

Approved for specific uses
LibraryNo account · this device only

Also known as: Thymalfasin · Tα1 · Zadaxin

Use at a glance

Thymosin Alpha-1

Studied for immune modulation and approved for specific uses in some countries, but not generally by FDA or EMA.

Which entry would you like to view?

Choose a source entry. Different products and study groups do not form one combined plan.

Study information · not a personal use plan

What amount?
1.6 mg
How often?
2 times per week · 180–365 days
What time of day?
Time of day not stated here; see the study plan
In what setting?
clinical context
How is it used?
An approved powder medicine has its own instructions for preparation and administration.
Does it need mixing?
Yes, if the product instructions require it. Use its specified liquid and volume; another brand may differ.
View preparationCheck sources
Overview of all entries

  • Thymosin Alpha-1 · clinical context

    Study information · not a personal use plan

    1.6 mg · 2 times per week · 180–365 days · Time of day not stated here; see the study plan

  • Thymosin Alpha-1 · community reports

    Online report · not medically verified

    1.6 mg · 2 times per week · 4–12 weeks · not reliably established

More factsPeptide · Immune research
Classification
Peptide · Immune research
Research focus
Studied for immune modulation and approved for specific uses in some countries, but not generally by FDA or EMA.
Evidence
In clinical trials
Status
Approved for specific uses

Approved uses exist, but dose, formulation, device and monitoring are product- and indication-specific. A community table cannot replace the prescribing information or a prescription.

Schedule explained in detailApproved medicine

Amount status

The reference documents 1.6 mg subcutaneous twice weekly, 3–4 days apart, from specific hepatitis contexts; community plans often run 4–12 weeks. Not a blanket wellness dose.

Profile evidence level: clinical.

Timing

Twice weekly in the described clinical contexts; indications and national approvals differ.

No individual recommendation.

Cycle/duration

Clinical hepatitis plans run 6–12 months, community plans considerably shorter. Not transferable to general 'immune boost' use.

No individual recommendation.

External community reference availableThe external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.

External community reference available

The external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.

Open community source

Mixing & calculations

Yes, if the product instructions require it. Use its specified liquid and volume; another brand may differ.

Simple syringe and pen calculator

Choose your device and enter your known values. One result appears below.

You know the total solution volume. Calculate the scale mark for your entered amount.

Which syringe or pen?
More syringes
How much substance is in the vial?

Total amount on the label—not the container size in ml.

What is the total solution volume?

This is the total solution after dissolving, not automatically the water to add. Follow the specific product's instructions for preparation.

Which known amount do you want to convert?

Your known input. The calculator does not choose a suitable amount.

Complete the three number fields to see a result.

The calculator chooses neither a dose nor a mixing liquid. It does not check sterility, stability or suitability for use.

What the units mean
  • mg / µg = substance amount. 1 mg = 1,000 µg.
  • ml = liquid volume, not substance amount.
  • U / clicks = device markings. Their meaning depends on the device scale.
Calculation and extra figures

Complete the three number fields to see a result.

Scale and precision notes

Arithmetic does not establish measurement accuracy. Displayed numbers may be rounded; very small numbers use scientific notation. Intermediate values may not be readable on your device. Do not round fractional clicks up or down.

U-100 is used as a volume scale: 100 U = 1 ml. It is not the substance amount.

Copy this value from your pen's instructions. A 3 ml cartridge does not tell you the volume delivered at 60 clicks.

Source for the U-100 scale
Formulas and individual stepsOpen only if you want the deeper explanation.

Formulas used

  • Concentration (µg/ml) = vial mg × 1,000 ÷ fluid ml
  • Volume (ml) = target µg ÷ concentration
  • U-100 units = volume ml × 100

Mixing process described by the reference

01

Verify inputs

Independently check label, fluid, expiry information and planned volume. Do not use unclear or damaged products.

02

Disinfect stoppers

The reference calls for separate alcohol swabs and sterile single-use materials.

03

Add fluid slowly

The calculated fluid is described as running down the inside wall rather than being forced directly onto the powder.

04

Dissolve gently

The vial is rolled or swirled gently, not shaken, until no visible solids remain.

05

Inspect visually

Cloudy, discoloured or particle-containing solution is discarded. Clarity does not prove sterility or identity.

06

Label and store by product data

Record concentration and date. Reliable manufacturer or pharmacy information takes precedence.

An internet guide cannot ensure aseptic preparation. Bacteriostatic water, sterile water and approved product diluents are not interchangeable; benzyl alcohol may be unsuitable for some people.

See calculation examplesFollow sample figures to understand mg, ml and scale markings.

Documented vial and fluid examples

The table shows only the arithmetic for explicitly stated inputs. It confirms neither vial content nor stability, sterility or an appropriate target amount.

10 mg · assumed final volume: 2 ml

Community calculation example
Calculated amount1.6 mg
Concentration5,000 µg/ml
U-10032 U
Volume0.32 ml

10 mg · assumed final volume: 1 ml

Community calculation example
Calculated amount1.6 mg
Concentration10,000 µg/ml
U-10016 U
Volume0.16 ml
All preparation informationProduct details and calculation examples from the available sources.

Reference arithmetic: 10 mg +2 ml =5 mg/ml; 1.6 mg =0.32 ml=32 U. At 10 mg +1 ml, 1.6 mg would be =16 U. A calculation example only, not a recommendation.

Reconstitution & quantitiesOpen basics, units and sources
Explained in very simple termsBefore reading any number: this page reports what a product label, study or online community states. It does not say what any person should use.

Amount

mg or µg describe the mass of a substance. That is not the same as ml of fluid or U on a syringe. The number is only the amount stated by the identified source.

Interval

The interval only describes the time stated between two points. For example, once every 7 days does not mean daily and never justifies catching up or doubling.

Cycle

A cycle is a stated period that may include breaks. A community cycle proves neither effectiveness nor safety and does not prevent long-term risks.

Reconstitution

Reconstitution means mixing powder with a defined volume of fluid. This changes concentration, not the total amount in the vial. On U-100, 100 U equals exactly 1 ml of volume.

Not a guide to misuse

All community figures are shown only to place widely circulated online protocols in context. They are not instructions for self-use, injection, performance enhancement or any other misuse. Approved figures apply only to the exact named product, approved indication and medical supervision.

Research, risks & more detailsMechanism, adverse effects, storage, comparisons and common questions.

Mechanism: what is supported and what does not follow

Synthetic version of an endogenous immune-modulating peptide

Thymosin Alpha-1 is classified as “Synthetic version of an endogenous immune-modulating peptide”. Studied for immune modulation and approved for specific uses in some countries, but not generally by FDA or EMA. This describes the investigated pathway but does not validate a community use, amount, route or combination.

01

Immune-modulating peptide

This studies how a peptide adjusts immune cell activity, similar to a dial that strengthens or dampens the immune response. Immune cell counts and inflammation markers are measured in studies.

02

Antimicrobial host defence

Researchers study how a naturally occurring defence peptide attacks bacteria and affects inflammation signals, similar to a first line of defence for skin and mucous membranes. Bacterial growth and immune markers are measured in the lab.

03

Thymus-derived blend

This concerns blends of peptides originally identified from thymus tissue and linked to immune maturation, similar to a collection of related signals rather than one single defined agent. Individual components are studied more often than the blend as a whole.

What communities discuss

These themes describe discussions and vendor claims. They do not prove benefit, safety, product identity or suitable use.

General wellness forums

Broader wellbeing impressions such as mood, sleep, and general feeling after using various products are exchanged here, usually without structured tracking. Such general impressions are not a substitute for targeted clinical examination.

Biohacker and longevity forums

Users compare self-assembled combinations of peptides aimed at influencing ageing processes or energy levels, often based on blood tests or subjective wellbeing scales. Personal self-experiments and marketing promises do not replace controlled long-term human studies.

Source and purity discussion

Discussion covers which vendors are seen as more trustworthy and how purity test results differ between batches. Such community assessments are based on limited samples and do not replace independent lab testing of each individual batch.

Adverse effects and safety risks

  • Modulating immune or antimicrobial signalling can affect inflammation, hypersensitivity, infection risk and unpredictable immune responses; route and formulation matter.
  • Local reaction, infection, abscess and contamination are possible with any injection that is not professionally manufactured and administered.
  • A label or clear appearance does not exclude unknown purity, wrong identity, endotoxins or concentration errors.

Do not self-use / obtain clinical review

  • Autoimmune disease, transplantation, immunosuppression, active infection, cancer and pregnancy require specialist assessment.
  • Acute symptoms, allergic reaction, breathing difficulty, chest pain, neurological deficits or severe abdominal pain require immediate medical care.
  • Children and adolescents, pregnancy/breastfeeding, and people with relevant disease should not be part of unsupervised experiments.

Monitoring and laboratory markers

  • Depending on indication, blood count, inflammatory markers, infection signs, liver/kidney function and immune parameters may be relevant; no universal community schedule exists.
  • Baseline, objective, measurement timing and stop criteria must be defined professionally in advance. Individual laboratory values cannot compensate for unknown product quality.

Evidence boundary

In clinical trials

It is not generally approved by the FDA or EMA, even though it is approved in some countries.

Clinical evidence

The substance is currently being studied in structured human clinical trials, but a general approval does not yet exist.

Thymosin alpha-1 is a single, defined immune peptide and is approved in some countries, unlike the non-standardised Thymalin preparation.

Storage and stability

  • The manufacturer label and prescribing information take priority. Storage instructions from a different product do not transfer.
  • Unapproved vials often lack dependable stability data before and after mixing; ‘2–8 °C’ or ‘28 days’ is not a universal standard.
  • Do not use after seal damage, particles, cloudiness, discoloration, unknown date or interrupted cold chain. Visual inspection does not prove sterility.

Troubleshooting and common errors

  • U-100 units measure volume, not drug amount: 100 U equals 1 mL. A wrong concentration makes every unit figure wrong.
  • Do not shake or dilute further to ‘fix’ cloudiness, particles or uncertain solubility; discard and obtain professional clarification.
  • Do not calculate a double or extra amount to compensate for missed use or an uncertain injection.
  • Without a COA, clear supplier, correct label and consistent vial information, identity is not confirmed.

Regulatory status and WADA

Approved for specific uses

Prescription active ingredient for defined indications in at least one jurisdiction; not offered here.

WADA 2026

The atlas has no explicit WADA flag for this profile. That does not automatically mean every form, route or related class is permitted in sport.

WADA — 2026 Prohibited List

Combinations / stacks

  • Combinations change effects, adverse effects and laboratory values; evidence for one substance does not establish the safety of a stack.
  • Overlapping pathways may add up. Hormonal, glucose, blood-pressure, coagulation, immune and sedating effects are important potential interactions.
  • Non-standardised blends prevent separate dosing, cause attribution and dependable reconstitution.

Frequently asked questions

Is an amount shown here a recommendation?

No. This page separates approved product information, study protocols and community information. No number or calculator is an individual dosing recommendation.

Does the U-100 calculator prove correct use?

No. It only converts mass, volume and syringe scale. It cannot check identity, purity, sterility, stability, solvent or medical suitability.

Can this profile be combined with other substances?

Safety of a combination cannot be inferred from a single-substance profile. Overlapping pathways, medicines and undefined blends can increase risk.

Which source controls when information conflicts?

For approved medicines, the current prescribing information and treating professional control. For research substances, conflict shows that no dependable self-use standard exists.

Are community claims clinical evidence?

No. Anecdotes can generate questions but do not replace controlled studies, regulatory review, or identity and quality testing.

Back to all 64 profilesOpen scientific atlas profile